Immunomodulatory effects of HBsAg vaccine and levamisole in chronic hepatitis B and hepatitis B carrier children

Turkish Journal of Gastroenterology

Volumn 16, Issue 4, 2005, Pages 188-193

  Demirci, Fikret ^a,b   Bayraktaroǧlu, Ziya ^a   Karaoǧlan, Murat ^a   Coşkun, Yavuz ^a   Karaoǧlan, Ilkay ^a   Okan, Vahap ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b University Building   (Turkey)

Author keywords

Children; Chronic hepatitis B; HBsAG vaccine; Hepatitis B carrier; Immunoglobulins; Levamisole; Lymphocyte subsets

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEVAMISOLE;

ADOLESCENT; ARTICLE; CD4 CD8 RATIO; CHILD; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HEPATITIS B; HUMAN; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; VIRUS CARRIER;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD3; ANTIGENS, CD4; CARRIER STATE; CD4-CD8 RATIO; CHILD; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEVAMISOLE; MALE; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33144489152     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12(2): 351-6.
2. Pol S, Couillin I, Michel ML, et al. Immunotherapy of hepatitis B by anti HBV vaccine. Acta Gastroenterol Belg 1998; 61(2): 228-33.
3. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Investig 1997; 99: 1472-7.
4. Chisari F, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-36.
5. Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442-9.
6. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-75.
7. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33(4): 963-71.
8. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56.
9. Yurdaydin C, Bozkaya H, Sahin T, et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg (-) chronic hepatitis B. J Viral Hepat 2005; 12(3): 262-8.
10. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
11. Pai SB, Bozdayi AM, Pai RB, et al. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemoter 2005; 49(7): 2618-24.
12. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, et al. YSDD: a novel mutation in HBV-DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003; 10(4): 256-65.
13. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
14. Chow YH, Huang WL, Chi WK, et al. Improvment of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997; 71: 169-78.
15. Michel ML, Pol S, Brechet C, et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001; 19: 2395-9.
16. Hui CK, Lau GK. Advances in immunomodulating therapy of HBV infection. Int J Med Sci. 2005; 2(1): 24-9.
17. Mancini M, Hadchouel M, Tiollais P, et al. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg transgenic mice: a possible way of circumventing 'nonresponse' to HbsAg. J Med Virol 1993; 39: 67-74.
18. Wang J, Zhu Q, Zhang T, et al. A pilot study on the combined therapy of granulocyte-macrophage colony-stimulating factor and hepatitis B vaccine on chronic hepatitis B virus carrier children. Chin Med J 2002; 115 (12): 1824-8.
19. Li YG, Chen M, Zhang DZ, et al. Clinical research on the treatment effect of autologous dendritic cell vaccine on the patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2003; 11(4): 206-8.
20. Holcombe RF, Li A, Stewart RM. Levamisole and interleukin-2 for advanced malignancy. Biotherapy 1998; 11(4): 255-8.
21. Tanphaichitra D, Srimuang S. Cellular immunity (T-cell subset using monoclonal antibody) in tuberculosis, melioidosis, pasteurellosis, penicilliosis; and role of levamisole and isoprinosine. Dev Biol Stand 1984; 57: 117-23.
22. Garszon MC. Levamisole treatment in HIV-infected Zambian children. Lancet 1992; 340: 1099-100.
23. Borisova AM, Novikova TA, Glazko AV. Effect of levamisole on cellular immunity indices in chronic bronchitis and chronic pneumonia patients. Ter Arkh 1984; 56(10): 29-31.
24. Fattovich G, Cadrobbi P, Crivellaro C, et al. Virological changes in chronic hepatitis type B treated with levamisole. Digestion 1982; 25(2): 131-7.
25. Bosch O, Moraleda G, Castillo I, et al. Treatment of chronic hepatitis B with recombinant Interferon alpha versus recombinant interferon alpha plus levamisole. J Hepatol 1993; 19(3): 437-41.
26. Ruiz-Moreno M, Garcia R, Rua MJ, et al. Levamisole and Interferon in children with chronic hepatitis B. Hepatology 1993; 18(2): 264-9.
27. Ren F, Hino K, Yamaguchi Y, et al. Cytokine-dependent anti-viral role of CD4 positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol 2003; 71(3): 376-84.
28. Jung MC, Gruner N, Zachoval R, et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002; 20(29-30): 3598-612.
29. Khanna A, Ojha KN, Gupta RM. Effect of levamisole as an immunomodulating agent in trophoblastic lesions. Indian J Pathol Microbiol 1993; 36(1): 32-7.
30. Scherak O, Smolen JS, Menzel AJ, et al. Effect of levamisole on immunological parameters in patients with systemic lupus erthematosus. Scand J Rheumatol. 1980; 9(2): 106-12.
31. Coullin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180(1): 15-26.
32. Abar SM, Abe SM, Masumato T, et al. Mecanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cell. J Hepatol 1999; 30(5): 755-64.
33. Isogawa M, Kakimi K, Kamamoto H, et al. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology 2005; 333(2): 293-300.
34. Gupta RK, Siber GR. Adjuvant for human vaccines - current status, problems and future prospects. Vaccine 1995; 14: 1263-75.
35. Pozsonyi T, Feher J, Jakab L. Lymphocyte populations in chronic active liver disease: in vitro effect of levamisole on T-lymphocyte populations. Allergol Immunopathol 1981; 9(1): 37-44.
36. Thomas HC, Freni M, Sanchez-Tapias J, et al. Peripheral blood lymphocyte populations in chronic liver disease. Clin Exp Immunol 1976; 26(2): 222-7.
37. Chemello L, Mondelli M, Bortolotti F, et al. Natural killer activity in patients with acute viral hepatitis. Clin Exp Imunol 1986; 64: 59-64.
38. Liberati M, Boreden EC, McBain JA, et al. Effect of levamisole on human natural killer and killer cell activity and production of interferons. Immunopharmacology 1982; 5(1): 11-8.
39. Kietduriyakul V, Charuchaimontri C. Serum immunoglobulin levels before and after hepatitis B vaccinations. J Med Assoc Thai 1991; 74(1): 19-23.